189 related articles for article (PubMed ID: 24857127)
1. Chemotherapy for lung cancers: here to stay.
Kris MG; Hellmann MD; Chaft JE
Am Soc Clin Oncol Educ Book; 2014; ():e375-80. PubMed ID: 24857127
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
3. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
4. Genomic alterations in lung adenocarcinoma.
Devarakonda S; Morgensztern D; Govindan R
Lancet Oncol; 2015 Jul; 16(7):e342-51. PubMed ID: 26149886
[TBL] [Abstract][Full Text] [Related]
5. Clinical response to crizotinib retreatment after acquisition of drug resistance.
Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
[No Abstract] [Full Text] [Related]
6. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
7. Present and future molecular testing of lung carcinoma.
Dacic S; Nikiforova MN
Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
[TBL] [Abstract][Full Text] [Related]
8. Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse.
Cortinovis D; Canova S; Abbate MI; Colonese F; Cogliati V; Bidoli P
Future Oncol; 2018 Sep; 14(22):2303-2317. PubMed ID: 30088419
[TBL] [Abstract][Full Text] [Related]
9. [Molecular diagnosis of lung cancer in association with treatment of choice].
Yatabe Y; Shibata N
Rinsho Byori; 2012 Aug; 60(8):786-95. PubMed ID: 23198539
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
Kumarakulasinghe NB; van Zanwijk N; Soo RA
Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
[TBL] [Abstract][Full Text] [Related]
11. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
[TBL] [Abstract][Full Text] [Related]
12. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
[No Abstract] [Full Text] [Related]
13. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
[No Abstract] [Full Text] [Related]
14. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
Benderra MA; Aspeslagh S; Postel-Vinay S; Bigot L; De Baere T; Loriot Y; Lacroix L; Massard C; Vassal G; André F; Soria JC
J Thorac Oncol; 2016 Feb; 11(2):e21-3. PubMed ID: 26845121
[No Abstract] [Full Text] [Related]
15. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
17. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
Moldvay J; Peták I
Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
[TBL] [Abstract][Full Text] [Related]
18. A banner year for immunotherapy and targeted therapy.
Carlisle JW; Ramalingam SS
Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
[No Abstract] [Full Text] [Related]
19. Overcoming Resistance to Targeted Therapies in Cancer.
Redmond KL; Papafili A; Lawler M; Van Schaeybroeck S
Semin Oncol; 2015 Dec; 42(6):896-908. PubMed ID: 26615134
[TBL] [Abstract][Full Text] [Related]
20. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]